- 1、本文档共1页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Hotline: 400-820-3792
Inhibitors • Screening Libraries • Proteins
www.MedChemE
Alflutinib
Cat. No.: HY-112870
CAS No.: 1869057-83-9
Synonyms: Furmonertinib; AST2818
分⼦式: C₂₈H₃₁F₃N₈O₂
分⼦量: 568.59
作⽤靶点: EGFR
作⽤通路: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
储存⽅式: Please store the product under the recommended conditions in
the Certificate of Analysis.
BIOLOGICAL ACTIVITY
⽣物活性 Alflutinib is a potent inhibitor of EGFR. Alflutinib inhibits EGFR active mutations as well as the T790M
acquired resistant mutation. Alflutinib has the potential for the research of cancer diseases, especially non-
small cell lung cancer (NSCLC) [1].
IC50 Target EGFR
体外研究 AST2818 is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation [1].
客户使⽤本产品发表的科研⽂献
• Patent. US20220177473A1.
See more customer validations on www.MedChemE
REFERENCES
[1]. Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A
phase1/2 Multi-Center Clinical Trial.
McePdfHeigh
您可能关注的文档
- 1-Naphthyl-PP1-hydrochloride-1-NA-PP-1-hydrochloride-DataSheet-生命科学试剂-MedChemExpress.pdf
- 3-Hydroxy-Repaglinide-d5-DataSheet-生命科学试剂-MedChemExpress.pdf
- 4-Octyl-Itaconate-DataSheet-生命科学试剂-MedChemExpress.pdf
- 10058-F4-DataSheet-生命科学试剂-MedChemExpress.pdf
- AB-680-ammonium-DataSheet-生命科学试剂-MedChemExpress.pdf
- AB-680-DataSheet-生命科学试剂-MedChemExpress.pdf
- AB928-DataSheet-生命科学试剂-MedChemExpress.pdf
- ABBV-167-DataSheet-生命科学试剂-MedChemExpress.pdf
- ABBV-CLS-484-DataSheet-生命科学试剂-MedChemExpress.pdf
- ACP-5862-DataSheet-生命科学试剂-MedChemExpress.pdf
文档评论(0)